Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 16,380 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Nervous System Disease Clear all
Completed No phase listed Observational Accepts healthy volunteers

Diffusion-Tensor Magnetic Resonance Imaging (MRI) and the Evaluation of Perinatal Brain Injury

NCT00131859
View directory record Official record
Conditions
Brain Injury, Fetus and Neonate
Interventions
Diffusion-tensor imaging
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
23 Weeks to 18 Months
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Magic Camp for Children With Hemiplegic Cerebral Palsy

NCT03620279
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Magic camp intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 16, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional

Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme

NCT00730262
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
TLN-4601
Drug
Lead sponsor
Thallion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Oct 16, 2026, 9:15 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

NCT03223103
View directory record Official record
Conditions
Glioblastoma
Interventions
Poly-ICLC, Tumor Treating Fields, Peptides
Drug · Device · Biological
Lead sponsor
Adilia Hormigo
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Recovery of Bladder and Sexual Function After Spinal Cord Injury

NCT03036527
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Activity-based locomotor training, Activity-based stand training, Activity-based upper arm ergometry, Activity-based training + spinal epidural stimulation
Procedure
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dapagliflozin In Alzheimer's Disease

NCT03801642
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
Jeff Burns, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 16, 2026, 9:15 PM EDT
Terminated Phase 3 Interventional Results available

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

NCT04963270
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 16, 2026, 9:15 PM EDT
Terminated Not applicable Interventional

Post-Brain Injury Walking and Balance Recovery Program

NCT05934773
View directory record Official record
Conditions
Acquired Brain Injury, Stroke, Traumatic Brain Injury
Interventions
KineAssist robotic treadmill
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma

NCT01722305
View directory record Official record
Conditions
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Recurrent Adult Diffuse Large Cell Lymphoma, Retinal Lymphoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 16, 2026, 9:15 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The TCU Division I Collegiate Athlete Study

NCT07006051
View directory record Official record
Conditions
Orthopaedic Injuries, Concussion (Diagnosis)
Interventions
Exposed group
Other
Lead sponsor
Texas Christian University
Other
Eligibility
17 Years to 30 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 16, 2026, 9:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cerebral Oxygen Metabolism in Children

NCT04157179
View directory record Official record
Conditions
Sickle Cell Disease, Cerebral Stroke
Interventions
Carbon Dioxide
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 50 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 16, 2026, 9:15 PM EDT
Not listed Not applicable Interventional

Mobility Rehab, a Therapist-assisted System for Gait Rehabilitation

NCT03869879
View directory record Official record
Conditions
Parkinson Disease, Stroke, Multiple Sclerosis, Gait Disorders, Neurologic, Gait Disorder, Sensorimotor, Gait, Unsteady, Gait Ataxia, Gait, Stumbling, Gait, Shuffling
Interventions
Feedback-assisted physical therapy, Traditional physical therapy
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
60 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salem, Oregon
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

NCT00626327
View directory record Official record
Conditions
Meningococcal Infections
Interventions
MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
7 Months to 1 Year
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
90
States / cities
Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients

NCT03417583
View directory record Official record
Conditions
Huntington Disease
Interventions
Protocol Intervention Group
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 16, 2026, 9:15 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration

NCT04584983
View directory record Official record
Conditions
Bilirubin Encephalopathy
Interventions
usual prescribed intralipid (UL) regimen, restricted prescribed intralipid (RL) regimen
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 27 Weeks
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

An Implantable Microneuromodulator for the Treatment of Chronic Shoulder Pain in Chronic Post-Stroke Subjects

NCT00567541
View directory record Official record
Conditions
Shoulder Pain Chronic
Interventions
Battery Powered Microneuromodulator (BBPM)
Device
Lead sponsor
Bioness Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Downey, California • Seattle, Washington • Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

NCT00915954
View directory record Official record
Conditions
Acromegaly, Type 2 Diabetes Mellitus
Interventions
Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 16, 2026, 9:15 PM EDT
Completed No phase listed Observational

Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes

NCT00004351
View directory record Official record
Conditions
Williams Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Shprintzen Syndrome, Smith-Magenis Syndrome, DiGeorge Syndrome, Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
0 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 16, 2026, 9:15 PM EDT
Active, not recruiting Not applicable Interventional

Kaneka Endovascular Embolization and Protection

NCT05563051
View directory record Official record
Conditions
Aneurysm Cerebral
Interventions
i-ED COIL
Device
Lead sponsor
Kaneka Medical America LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Grand Blanc, Michigan • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 16, 2026, 9:15 PM EDT
Recruiting No phase listed Observational

Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline

NCT05556395
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Error Augmentation for Neurorehabilitation

NCT01574495
View directory record Official record
Conditions
Stroke
Interventions
Error Augmentation
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

NCT01967823
View directory record Official record
Conditions
Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer
Interventions
Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 16, 2026, 9:15 PM EDT
Completed No phase listed Observational Results available

Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs

NCT00386880
View directory record Official record
Conditions
Migraine
Interventions
Sounds
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 16, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

NCT04072380
View directory record Official record
Conditions
Narcolepsy
Interventions
SUVN-G3031, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 16, 2026, 9:15 PM EDT